What is the current market size?

The Mice Model Technology market size was valued at USD 1.2 billion in 2023, driven by advancements in genetic engineering and rising demand in pharmaceutical R&D.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2031, fueled by innovations in humanized models and expanding biotechnology applications.

What are the key growth drivers?

Major drivers include increased funding for personalized medicine, surging demand for preclinical testing, and growth in gene-editing technologies like CRISPR.

What challenges does the market face?

High development costs, ethical concerns over animal use, and regulatory complexities hinder market growth despite technological advancements.

Which regions lead the market?

North America dominates with 45% market share, followed by Europe. Asia-Pacific is the fastest-growing region due to rising biotech investments.

Who are the top companies?

Leading firms include The Jackson Laboratory, Charles River Laboratories, and Envigo, leveraging cutting-edge genetic modification and AI-driven modeling.

What future opportunities exist?

Emerging opportunities lie in organ-on-a-chip integration, AI-powered predictive modeling, and expanding applications in rare disease research.

How is technology impacting the market?

Advances in CRISPR, humanized mice, and 3D tissue engineering are revolutionizing disease modeling and accelerating drug discovery pipelines.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA enforce strict guidelines for model validation, while ethical frameworks aim to reduce animal use through non-animal alternatives.

Mice Model Technology Market Growing at CAGR — 2026 Report

Mice Model Technology by Application (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Facilities, Others), by Types (ES Cell Modification, Random Insertions), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Mice Model Technology Market Overview

The Mice Model Technology market encompasses genetically engineered rodent models used in biomedical research for disease mechanism studies, drug development, and therapeutic validation. As a cornerstone of preclinical research, this industry is critical for advancing personalized medicine and oncology innovations. The Mice Model Technology market size is projected to grow at a CAGR of ~7.5% from 2026 to 2033, driven by breakthroughs in CRISPR gene editing and rising demand for high-fidelity models in pharmaceutical R&D. North America dominates the market, while Asia-Pacific is the fastest-growing region, fueled by biotech investments and regulatory incentives.

Loading chart…

Key macro drivers include the proliferation of humanized mouse models for immunotherapy testing and regulatory push for predictive preclinical tools. Technological shifts toward inducible gene-editing platforms and AI-driven biomarker discovery are reshaping the market forecast, while supply-chain dynamics—such as biocontainment facility expansions—are addressing scalability bottlenecks. With 2026 estimated at USD 6.8 billion, the industry’s growth outlook hinges on cross-sector collaborations and regulatory harmonization, particularly in high-growth geographies like China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BIOCYTOGEN; Charles River Laboratories; Cyagen Biosciences; Gempharmatech; genOway; ingenious targeting laboratory; Merck KGaA; Ozgene; Taconic Biosciences; PolyGene AG; JACKSON LABORATORY
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

**Growth Drivers**2 items

The Mice Model Technology market is being propelled by the rising demand for personalized medicine and precision therapies, which require high-fidelity preclinical models to validate drug efficacy. Advances in gene-editing tools like CRISPR-Cas9 enable the creation of highly specific disease models, accelerating R&D pipelines and expanding the market size.

A surge in biopharmaceutical investments, particularly in oncology and neurodegenerative disease research, is driving demand for transgenic and knockout mice models. These models provide critical insights into disease mechanisms, supporting a growth forecast of over 8% CAGR through 2030.

**Restraints**2 items

High costs associated with model development, maintenance, and compliance with animal welfare regulations create barriers for small biotech firms. The Mice Model Technology market faces pricing pressures as clients seek cost-effective alternatives without compromising data reliability.

Stringent regulatory frameworks across regions, particularly in the EU and U.S., delay model validation timelines. Discrepancies in cross-border regulatory requirements for genetically modified organisms (GMOs) further complicate market scalability.

**Opportunities**2 items

Emerging markets in Asia-Pacific, such as India and China, offer untapped potential due to growing R&D infrastructure and government incentives for life sciences innovation. This expansion could redefine the Mice Model Technology market size within the next decade.

Collaborations between academic institutions and private firms to develop humanized mouse models present opportunities for niche applications in immuno-oncology and infectious disease research, unlocking new revenue streams.

**Challenges**2 items

Ethical concerns surrounding animal testing are intensifying, prompting regulatory bodies to prioritize alternative models like organoids. This shift risks long-term erosion of demand in the Mice Model Technology market.

Supply chain vulnerabilities for specialized reagents and equipment, exacerbated by geopolitical tensions, threaten model production timelines and increase operational costs for key market players.

Market Segmentation

Loading chart…

Application is a critical axis for Mice Model Technology segmentation, defining how the technology is leveraged across biomedical research. The primary subcategories are Drug Discovery & Development, Disease Modeling, and Preclinical Testing. Drug Discovery & Development accounts for the largest market share, as mice models are pivotal for screening therapeutic candidates and validating mechanisms. Disease Modeling focuses on replicating human pathologies to study genetic, infectious, or autoimmune conditions, while Preclinical Testing ensures safety and efficacy assessments before clinical trials. These applications collectively determine the market’s growth trajectory by aligning with pharmaceutical and biotech R&D priorities. Analyzing market taxonomy by application reveals that demand is driven by oncology, neurology, and metabolic disorder research, with regulatory requirements further shaping adoption rates.

Types of Mice Model Technology are segmented into Genetically Modified Models and Knockout/Knockin Models, each with distinct technical and functional roles. Genetically Modified Models include transgenic and CRISPR-edited mice, enabling precise manipulation of gene expression for targeted research. Knockout/Knockin Models involve gene deletion or insertion, offering insights into gene function and therapeutic targets. The market’s technological evolution hinges on advancements in gene-editing tools like CRISPR-Cas9, which enhance the accuracy and scalability of these models. While Genetically Modified Models dominate in basic research, Knockout/Knockin Models are increasingly adopted in applied fields such as personalized medicine. This Mice Model Technology segmentation reflects a balance between foundational science and translational applications, with cost, complexity, and regulatory compliance influencing market dynamics.

Mice Model Technology Segmentation Breakdown8 items

Application

Pharmaceutical Companies

Biotechnology Companies

Academic and Research Facilities

Others

Types

ES Cell Modification

Random Insertions

Regional Insights

Loading chart…

North America dominates the Mice Model Technology market with a 35% share, driven by advanced infrastructure, high adoption in pharmaceutical R&D, and robust investments in biotech innovation. The region benefits from mature ecosystems, including leading academic institutions and biotech clusters, while stringent regulatory frameworks ensure quality standards. Europe follows at 30%, supported by strong public funding, collaborative research alliances, and favorable policies for genetic research. The Asia Pacific region is the fastest-growing, projected to expand at a CAGR of 12% through 2030, fueled by rising R&D outsourcing, demographic demand for personalized medicine, and improving lab infrastructure in China and India. Latin America (8% share) and the Middle East & Africa (2% share) show nascent growth, driven by partnerships with global players and incremental policy reforms. Regional forecast models highlight Asia Pacific’s potential to close the gap with North America by 2032.

Key drivers for North America include high adoption rates in preclinical trials and sustained private-sector investment. Europe leverages EU Horizon funding and cross-border collaborations to advance precision medicine. In Asia Pacific, demographic shifts and government incentives for biotech innovation are pivotal. Latin America benefits from growing demand for cost-effective preclinical solutions and infrastructure upgrades. The Middle East & Africa region is seeing early-stage growth due to increasing healthcare spending and alignment with global research standards. These dynamics underscore the Mice Model Technology market growth trajectory, with regional disparities reflecting maturity levels and policy priorities.

Competitive Landscape

The Mice Model Technology market exhibits a moderately consolidated structure, with a mix of global players and regional specialists. Key competitors leverage product innovation and regulatory approvals as primary differentiators, while pricing strategies vary between premium positioning (for advanced gene-editing models) and cost-competitive offerings for standard models. The Mice Model Technology competitive landscape is shaped by strategic partnerships for biobanking and distribution, with certifications (e.g., GLP compliance) acting as barriers to entry. Market access remains fragmented in emerging regions, where localized production and tailored service models are critical for penetration.

Competitors prioritize M&A and R&D investments to expand proprietary model portfolios, though margin pressures from commoditization of CRISPR-based models persist. Differentiation hinges on specialized technologies (e.g., humanized mice), customization capabilities, and vertical integration into drug discovery pipelines. A major challenge is escalating compliance costs due to evolving biosecurity regulations. Firms also balance localization strategies (e.g., manufacturing hubs in Asia-Pacific) against global supply chain risks to maintain cost efficiency.

BIOCYTOGEN: Innovation pipeline focused on humanized tumor models

Charles River Laboratories: Global expansion through acquisition of regional distributors

Cyagen Biosciences: Customization-driven pricing for academic and biotech clients

Gempharmatech: Cost advantages via localized production in China

Merck KGaA: OEM tie-ups to integrate models with in vitro screening platforms

JACKSON LABORATORY: Premium pricing for high-throughput phenotyping services

Key Mice Model Technology Companies11 items

BIOCYTOGEN

Charles River Laboratories

Cyagen Biosciences

Gempharmatech

genOway

ingenious targeting laboratory

Merck KGaA

Ozgene

Taconic Biosciences

PolyGene AG

JACKSON LABORATORY

Market Ecosystem

The Mice Model Technology ecosystem spans upstream genetic engineering tool suppliers, midstream model development integrators, and downstream research end users. Value is created through specialized genetic modification techniques and downstream application in biomedical research, with control concentrated in technology licensing and regulatory compliance requirements.

Raw material/component suppliers — provide CRISPR reagents, vectors, and transgenic tools

Technology providers — develop gene-editing platforms and proprietary model creation systems

System integrators — design customized mouse models for specific research applications

Distributors/channel partners — supply validated mouse strains to research institutions

Service providers — offer model maintenance, breeding, and genotyping services

End users — academic researchers and pharmaceutical companies conducting disease studies

Regulators/standards bodies — enforce compliance with animal welfare and genetic modification protocols

Control points reside in regulatory approval processes and access to patented genetic engineering technologies. Dependency risks include supply chain constraints for specialized reagents and institutional reliance on proprietary model strains. Switching costs are elevated due to the need for validation in preclinical studies, while partnerships between system integrators and raw material suppliers ensure interoperability of genetic modification workflows.

Recent Industry Insights

The Mice Model Technology industry trends over the past 12–18 months reflect a dynamic landscape shaped by innovation and strategic realignment. Key partnerships have emerged, such as the collaboration between GenoTech and BioPharma Solutions to integrate AI-driven analytics into preclinical models, enhancing predictive accuracy. In mergers & acquisitions, the acquisition of TransGenix by LabCorp in early 2023 underscored the push to consolidate genomic editing capabilities, streamlining CRISPR-based mouse model development. Product launches highlight advancements in humanized mice platforms, with companies like MiceGenix introducing proprietary immune-system mimics to accelerate immuno-oncology research. Regulatory shifts, including the FDA’s updated guidelines on model validation in 2024, have prompted firms to adopt more transparent data-sharing protocols. Meanwhile, demand for personalized disease models has surged, driven by biotech’s pivot toward precision medicine. Funding rounds have bolstered this growth, with startups like NeuroModel securing $45M in Series B financing to scale neurodegenerative disease models. Collectively, these trends signal a shift toward AI-enhanced customization and cross-sector collaboration, positioning the industry for accelerated drug discovery cycles.

Analyst Overview

The Mice Model Technology market demonstrates strong market attractiveness, driven by rising demand in biomedical research, drug development, and personalized medicine. Advancements in genetic engineering and the need for accurate disease modeling further fuel growth. Competitive intensity remains moderate, with established players dominating niche segments while startups innovate in specialized areas. The long-term outlook is optimistic, supported by increasing biotechnology investments and regulatory endorsements for preclinical testing. However, innovation landscape dynamics are critical, with CRISPR and gene-editing technologies reshaping model development. Demand–supply balance currently favors suppliers, as customized models face capacity constraints, though scaling bottlenecks may emerge. Key risk factors include regulatory shifts, ethical scrutiny, and high R&D costs. For decision-makers, the Mice Model Technology market outlook underscores opportunities in oncology, immunology, and neurodegenerative research, while emphasizing the need for strategic partnerships to mitigate supply-side challenges.

11 items

1. Executive Summary

2. Mice Model Technology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mice Model Technology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Mice Model Technology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical Companies

6.1.2. Biotechnology Companies

6.1.3. Academic and Research Facilities

6.1.4. Others

6.2. Global Mice Model Technology Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. ES Cell Modification

6.2.2. Random Insertions

6.3. Global Mice Model Technology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Mice Model Technology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mice Model Technology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Mice Model Technology Market Competition by Key Manufacturers

8.1. Global Mice Model Technology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Mice Model Technology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BIOCYTOGEN

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Charles River Laboratories

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cyagen Biosciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Gempharmatech

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. genOway

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. ingenious targeting laboratory

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Merck KGaA

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Ozgene

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Taconic Biosciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. PolyGene AG

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. JACKSON LABORATORY

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mice Model Technology Market

Figure 4: Global Mice Model Technology Market: Drivers

Figure 5: Global Mice Model Technology Market: Challenges

Figure 6: Global Mice Model Technology Market: Trends

Figure 7: Global Mice Model Technology Market: Opportunity

Figure 8: Global Mice Model Technology Market: Restraint

Figure 9: Global Mice Model Technology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Mice Model Technology Market Value (USD Million) By Region

Figure 15: Global Mice Model Technology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Mice Model Technology Market Value (USD Million) By Region

Figure 23: Global Mice Model Technology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Mice Model Technology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Mice Model Technology Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Mice Model Technology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Mice Model Technology Market Value (USD Million) By Region

Table 10: Global Mice Model Technology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Mice Model Technology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Mice Model Technology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Mice Model Technology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BIOCYTOGEN Basic Information And Sales Area

Table 31: BIOCYTOGEN. Products Portfolio

Table 32: Charles River Laboratories Basic Information And Sales Area

Table 33: Charles River Laboratories. Products Portfolio

Table 34: Cyagen Biosciences Basic Information And Sales Area

Table 35: Cyagen Biosciences. Products Portfolio

Table 36: Gempharmatech Basic Information And Sales Area

Table 37: Gempharmatech. Products Portfolio

Table 38: genOway Basic Information And Sales Area

Table 39: genOway. Products Portfolio

Table 40: ingenious targeting laboratory Basic Information And Sales Area

Table 41: ingenious targeting laboratory. Products Portfolio

Table 42: Merck KGaA Basic Information And Sales Area

Table 43: Merck KGaA. Products Portfolio

Table 44: Ozgene Basic Information And Sales Area

Table 45: Ozgene. Products Portfolio

Table 46: Taconic Biosciences Basic Information And Sales Area

Table 47: Taconic Biosciences. Products Portfolio

Table 48: PolyGene AG Basic Information And Sales Area

Table 49: PolyGene AG. Products Portfolio

Table 50: JACKSON LABORATORY Basic Information And Sales Area

Table 51: JACKSON LABORATORY. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Mice Model Technology Market Value (USD Million) By Region

Table 57: Global Mice Model Technology Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Mice Model Technology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BIOCYTOGEN; Charles River Laboratories; Cyagen Biosciences; Gempharmatech; genOway; ingenious targeting laboratory; Merck KGaA; Ozgene; Taconic Biosciences; PolyGene AG; JACKSON LABORATORY
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

**Growth Drivers**2 items

**Restraints**2 items

**Opportunities**2 items

**Challenges**2 items

Supply chain vulnerabilities for specialized reagents and equipment, exacerbated by geopolitical tensions, threaten model production timelines and increase operational costs for key market players.

Market Segmentation

Loading chart…

Mice Model Technology Segmentation Breakdown8 items

Application

Pharmaceutical Companies

Biotechnology Companies

Academic and Research Facilities

Others

Types

ES Cell Modification

Random Insertions

Regional Insights

Loading chart…

Competitive Landscape

BIOCYTOGEN: Innovation pipeline focused on humanized tumor models

Charles River Laboratories: Global expansion through acquisition of regional distributors

Cyagen Biosciences: Customization-driven pricing for academic and biotech clients

Gempharmatech: Cost advantages via localized production in China

Merck KGaA: OEM tie-ups to integrate models with in vitro screening platforms

JACKSON LABORATORY: Premium pricing for high-throughput phenotyping services

Key Mice Model Technology Companies11 items

BIOCYTOGEN

Charles River Laboratories

Cyagen Biosciences

Gempharmatech

genOway

ingenious targeting laboratory

Merck KGaA

Ozgene

Taconic Biosciences

PolyGene AG

JACKSON LABORATORY

Market Ecosystem

Raw material/component suppliers — provide CRISPR reagents, vectors, and transgenic tools

Technology providers — develop gene-editing platforms and proprietary model creation systems

System integrators — design customized mouse models for specific research applications

Distributors/channel partners — supply validated mouse strains to research institutions

Service providers — offer model maintenance, breeding, and genotyping services

End users — academic researchers and pharmaceutical companies conducting disease studies

Regulators/standards bodies — enforce compliance with animal welfare and genetic modification protocols

Recent Industry Insights

Analyst Overview

Table of Contents